<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pepsreview.com/articles/denmark-31-patients-compensated-semaglutide-naion-vision-loss</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-21</news:publication_date>
      <news:title><![CDATA[Denmark Has Now Paid 31 Patients Over Semaglutide Vision Loss, With 34 Claims Still Open]]></news:title>
      <news:keywords>NAION, semaglutide vision loss, Wegovy, Ozempic, Denmark patient compensation, GLP-1 eye warning, FDA NAION label, peptide regulation</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/tirzepatide-surmount-adolescents-72-week-bmi-results</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-20</news:publication_date>
      <news:title><![CDATA[Tirzepatide Cut Adolescent BMI 18.5% in 72 Weeks, With GI Side Effects in Four of Five]]></news:title>
      <news:keywords>tirzepatide adolescents, SURMOUNT-ADOLESCENTS, pediatric obesity, GLP-1 teenagers, JAMA tirzepatide trial, adolescent BMI reduction, GLP-1 side effects</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/survodutide-phase-3-data-no-fda-filing-gray-market-vials</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19</news:publication_date>
      <news:title><![CDATA[Survodutide Has Phase 3 Data and No FDA Filing: What That Means for the Vials Being Sold Now]]></news:title>
      <news:keywords>survodutide, BI 456906, glucagon GLP-1 dual agonist, FDA approval status, SYNCHRONIZE-1, MASH, research peptides, unapproved GLP-1</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/fda-warning-letter-wave-same-as-wegovy-compounded-claims</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19</news:publication_date>
      <news:title><![CDATA[FDA's Warning-Letter Wave Targets the 'Same as Wegovy' Ad Claim]]></news:title>
      <news:keywords>FDA warning letters, compounded GLP-1, semaglutide, tirzepatide, telehealth enforcement, misbranding, sameness claims</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/health-canada-approves-foundayo-first-daily-glp1-pill</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19</news:publication_date>
      <news:title><![CDATA[Health Canada Approves Foundayo, the First Daily GLP-1 Pill for Weight Loss in Canada]]></news:title>
      <news:keywords>Health Canada, Foundayo, orforglipron, oral GLP-1, weight loss pill, Eli Lilly, Wegovy pill, type 2 diabetes</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/pfizer-blackstone-1-5b-berobenatide-monthly-glp1-trials</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19</news:publication_date>
      <news:title><![CDATA[Pfizer Lines Up $1.5B From Blackstone to Fund Monthly GLP-1 Peptide Trials]]></news:title>
      <news:keywords>berobenatide, Pfizer Blackstone deal, monthly GLP-1 peptide, berobenatide Phase 3, obesity drug financing, GLP-1 research, peptide verification</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/step-young-nejm-tolerability-growth-rebound-children</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19</news:publication_date>
      <news:title><![CDATA[STEP Young in NEJM: 70% Vomiting, a 1.3-Inch Growth Gap, and BMI That Rebounded Off Treatment]]></news:title>
      <news:keywords>STEP Young, semaglutide children, Wegovy pediatric trial, GLP-1 side effects, pediatric obesity, NEJM semaglutide, GLP-1 growth</news:keywords>
    </news:news>
  </url>
</urlset>